PERFORMANCE IN INITIATING CLINICAL RESEARCH (PI) CLINICAL TRIAL FEEDBACK PROCESS HRA APPROVED TRIALS
|
|
- Stella Fletcher
- 5 years ago
- Views:
Transcription
1 PERFORMANCE IN INITIATING CLINICAL RESEARCH (PI) CLINICAL TRIAL FEEDBACK PROCESS HRA APPROVED TRIALS Version Control New document 1
2 Acronyms CTP DSC DSS FPR HRA MHRA REC SOP Clinical Trial Performance Date Site Confirmed Date Site Selected First Patient Recruitment Health Research Authority Medicines and Healthcare products Regulatory Agency Research Ethics Committee Standard Operating Procedure Purpose This Standard Operating Procedure (SOP) describes the process of data feedback for the Performance in Initiating Clinical Research exercise which informs the NIHR performance metrics for providers of NHS services. The intention of this SOP is to outline clearly and transparently the way in which the feedback process is applied to submitted clinical trials; to promote consistency of execution of the process and common mutual understanding of expectations and requirements. With the removal of the 70 day benchmark as of Q , a feedback process to improve reporting accuracy will replace the previous adjustment process. The objective of the feedback process is to identify where NHS providers have reported delays in initiating clinical trials, but the explanation of these delays is unclear or incomplete. These trials will continue to be used to evaluate the broader performance of the clinical research system both locally and nationally. Audience The primary audience of this SOP is the Clinical Trial Performance (CTP) Team at the NIHR Central Commissioning Facility; to use during the analysis process following quarterly submissions. This document is also intended to help and support R&D Managers, R&D Data Managers and other R&D staff, both new to the exercise and those from established submitters, to complete their quarterly returns to the NIHR CCF in a way that achieves consistency within and across providers of NHS services. Background The Government wishes to see a dramatic and sustained improvement in the performance of providers of NHS services in initiating and delivering clinical research. The aim is to increase the number of patients who have the opportunity to participate in research and to enhance the nation s attractiveness as a host for research. Performance in Initiating Clinical Research aims to assess the interval from the date the site is selected to recruitment of the first patient to a trial. The Department of Health places a contractual obligation on providers of NHS services contracted through the NIHR; to submit data and publish outcomes against the initiation of all clinical trials and delivery to time and to target for commercial clinical trials. More information and all related documents to support the submission process can be accessed at 2
3 Consistency in the feedback and analysis of data is important for providers to understand their quarterly performance against other providers, for the accuracy of publicly available published data. Providers are responsible for the submission of complete and accurate information. Term Date of First Patient Recruitment (FPR) Date Site Confirmed Date Site Selected Feedback process Matched trial Mismatched trial Need More Info Reason for delay Source of delay Submission period Submission window Description Means the date the first eligible patient consented to the study. Date of the last contract signature of all the organisations involved (i.e. sponsor, site, 3rd party) or date of final written agreement of statement of activity (as applicable) Date on the received by the site providing the minimum defined documents to enable site to commence arrangement and/or confirmation of local capacity and capability as applicable representing that the site has been selected to take part in the study. Where the is also the site, this is the date of the HRA initial assessment letter. 1 Process by which trials which have reported delays are assessed for completeness and clarity. Trial where the reason for delay and the source of delay are consistent with each other and with the durations between DSS and FPR. Trial where the selected source of delay does not correspond to the reason for delay and/or the durations between DSS and FPR. Term given to a trial where no reason and/or source of delay has been selected, or where the information given is not sufficient to match the trial. Relating to the list of possible reasons for delay to clinical trials initiation, cited by the provider of NHS services for each clinical trial where a delay has been noted. The list of possible reasons can be found in Appendix 1 of this document. Indicates which party was responsible for the delay: NHS Provider//Both/. The period (usually 30 days) between the end of the quarter and the submission deadline The timeframe for which data must be submitted by the provider Feedback Process The feedback process is now comprised only of a data quality assessment; this feedback is intended for providers to review their data in future submissions and not for in-quarter changes. Because there is no longer a benchmark by which trials will be judged, records will not be removed from the analysis even if the delay was out of control of the NHS provider. The feedback will highlight where providers can give additional detail to create a clear and complete picture of delays. For any 1 3
4 additional information about platform validation of data quality, please refer to the CTP Submission Platform Instructions. 2 Data Issue Type REC number not recognised Incorrect date format Data outside the submission window Data type mismatch No source of delay and/or no reason for delay First Patient Recruited? status is Yes - Date Unavailable HRA approval record not found Action Feedback to trust; trials will not be excluded from the analysis solely on the basis of an unrecognised REC number If the date is invalid or in a format which will cause formulae to fail, the dates and durations will be deleted. If the format of the date is incorrect but the information is clear, then the record is cleaned (i.e., 1-Jan-15 to 01/01/2015). For more information, please refer to the CTP Submission Platform Instructions. 2 Usually occurring with Date of First Patient Recruitment; record will be cleaned to how it looked on the last day of the quarter (date of FPR deleted, duration from DSS to FPR deleted, First Patient Recruited? changed to No ). When numerical data appears in text fields or vice versa; these types of errors are usually picked up by the submission validation and are therefore quite rare. Where the intended information is clear (i.e., the inversion of two columns), the record will be cleaned; if there is any doubt about the intended information, the record will be excluded from analysis. Marked as Need More Info, and included in the dataset. Trials will be treated as if a first patient has not been recruited, since the Date of First Patient Recruited will be blank. If the record cannot be matched to the HRA data using the REC or IRAS number, the following comments may be returned, depending on query results from the HRA: Pre- HRA, Non-clinical trial or Non-HRA approval. No Data comment will also be returned for HRA Submission Date / Date Study Initiated, HRA Country, HRA Approval Status, and HRA Approval Date if record cannot be matched to HRA data. All trials carried forward from the previous quarter to the current quarter will be compared to the previous quarter's matching status and handled according to the following scenarios and actions: Scenario Trial data not changed, trial previously reported delays Action Matching as previous quarter Trial data updated Trial data not changed, but the feedback guidelines have changed and trusts have been notified at least 10 days before the end of the quarter Matching reassessed Matching reassessed 2 ons%20published.pdf 4
5 The following table describes the range of scenarios involving omission of data or the selection of a single delay reason, what is expected in the way of supporting information and the action in respect of match/mismatch: Scenario Sub-Category Expected Source of Delay Comments Notes/Action Please briefly explain the reason for A - Relevant delay to permissions (i.e., the permissions delayed HRA approval process not subcategory). Please briefly explain and not granted in completed in time the nature of the delay and why the time chosen source of delay is appropriate. B - Suspended by Study suspended by sponsor at all sites Study suspended by sponsor at this site C - Closed by Study closed by sponsor at all sites Study closed by sponsor at this site D - Delays delay in provision of study documentation (e.g. pharmacy or laboratory manual) delay in provision of IMP, device or equipment delay through protocol or research application amendments delayed site initiation visit delayed confirmation of study open to recruitment at site (i.e., green light) sponsor delay (i.e., the subcategory) in sponsor delay (i.e., the subcategory) in Please briefly explain the nature of the sponsor delay (i.e., the subcategory) in sponsor delay (i.e., the subcategory) in sponsor delay (i.e., the subcategory) in 5
6 Scenario Sub-Category Expected Source of Delay Comments Notes/Action Planned and agreed later start or E - Staff Availability Issues F No Eligible Patients Seen delay intrinsic in study design (e.g. planned later start, followon study, dependency on unpredictable event e.g. flu epidemic) staff availability (annual leave, sickness absence, staff issue / shortage) training (e.g. GCP, protocol specific training, etc.) staff availability (annual leave, sickness absence, staff issue / shortage) training (e.g. protocol specific training etc.) Patients screened but no eligible patients identified Strict patient eligibility criteria / Low recruitment target NHS Host Site's inadequate planning / feasibility arrangements to see patients delay (i.e., the subcategory) in the Please briefly explain provider training issue (i.e., the subcategory) in the Please briefly explain sponsor staffing issue (i.e., the subcategory) in the Please briefly explain sponsor training issue (i.e., the subcategory) in the Please indicate the reason no patients were seen (i.e., the subcategory) in Please indicate the reason no patients were seen (i.e., the subcategory) in NHS staff issues such as annual leave, sick leave, maternity leave, etc. are expected to be within NHS provider's control. staff issues such as annual leave, sick leave, maternity leave, etc. are expected to be within sponsor's control. 6
7 Scenario Sub-Category Expected Source of Delay Comments Notes/Action G No Eligible Patients Consented H - Contracting Delays Eligible patients seen chose not to participate in study (e.g. Personal reasons, frequent study visits, reluctance to participate in placebo arm, preference of treatment choice, etc.) Eligible patients seen chose not to participate in study: NHS Host Site's inadequate planning /arrangements to consent patients Contracting / costing delays (including service support costing and excess treatment costing, etc.) Both delay and why the chosen source of delay is appropriate. I - Rare Diseases (Please see submission guidelines 1 ) Rare or very rare diseases studies (as defined in the guidance) J - Other Other - specify in comment Both Please only use other if no other reason explains the delay. Comments must always be included. Please briefly explain the nature of the delay and why the chosen source of delay is appropriate. Trial will be marked Need More Info if no comments are entered, or if the comments do not adequately explain the delay and the choice of source of delay. 7
8 Complex delays with multiple reasons for delay and/or sources of delay It is important to capture all delays which occurred between DSS and FPR in order to gain a more complete understanding of why trials have not progressed as expected. As indicated in the table above, please provide reasons for delay between DSS and DSC and between DSC and FPR, if applicable. As the overall aim of the exercise is to reduce the amount of time to initiate clinical trials, it is important to capture delays which could have been avoided or mitigated in order to highlight opportunities for process improvement. If there are multiple reasons for delay, please include all of these reasons in the record. Because reasons are not currently ranked or prioritised in the submission platform, it is not possible to objectively differentiate them in the analysis. However, providers are welcome (but not required) to indicate which reason or reasons contributed most significantly to the delay. Where there are also multiple sources of delay associated with these reasons, the CTP Team will accept in good faith the source of delay which the provider associates with the most significant reason for delay as long as the rationale is sufficiently explained in the 8
PERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES
PERFORMANCE IN INITIATING AND DELIVERING CLINICAL RESEARCH INFORMATION SUBMISSION GUIDELINES Version Control Item 19 Items 25, 26 Item 29 Update to the Publication requirements Update of Submission Timetable
More informationSetting up new studies where NBT are sponsor
Setting up new studies where NBT are sponsor Task Why Task Should Happen When Task Should Happen Who Should Complete Task How Task is Completed TASK 1: Apply for confirmation that NBT can sponsor the study
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 14. Amendments to Research Studies
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 14. Amendments to Research Studies Amendments are changes made
More informationResearch & Development. J Illingworth and S Moffat. Research, pharmacy and R&D staff
Department Title of SOP Research & Development SOP reference no: R&D GCP SOP 08 Authors: Reviewed by Current version number and date: J H Pacynko J Illingworth and S Moffat Version 4, 04.02.19 Next review
More informationSally Burtles, Director of Research Services & Business Development
Standard Operating Procedures (SOP) for: Process for Researchers - Amendments for Sponsored Studies (including halting studies and early termination) SOP Number: 17c Version Number: 2.0 Effective Date:
More informationConfirming Research Study Capacity and Capability
Title: Outcome Statement: Written By: Confirming Research Study Capacity and Capability Researchers will be informed about the procedures and requirements for obtaining permission to conduct a research
More informationOnce notified of the end of trial, a Research Manager, on behalf of the Sponsor, will contact the CI to arrange a close down monitoring visit.
1. INTRODUCTION This SOP has been produced in accordance with the requirements of The Medicines for Human Use (Clinical Trials) Regulations 2004, Medicines for Human Use (Clinical Trials) Amendment Regulations
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Non Compliance and Serious Breach Reporting SOP-RES-017 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016 Review Date 10 th Nov
More informationTrust Board Meeting: Wednesday 8 July 2015 TB
Trust Board Meeting: Wednesday 8 July 2015 Title NIHR Reporting of R&D Metrics Status History A paper for information The Trust Management Executive received an update on the performance of the Trust with
More informationDocument Title: Annual Progress Reports (APRs) Document Number: 056
Document Title: Annual Progress Reports (APRs) Document Number: 056 Version: 1 Ratified by: Committee Date ratified: 30/11/2017 Name of originator/author: Directorate: Department: Name of responsible individual:
More informationUK COMPATIBILITY HEALTH RESEARCH AUTHORITY APPROVAL WHAT IS HEALTH RESEARCH AUTHORITY APPROVAL?
UK COMPATIBILITY HEALTH RESEARCH AUTHORITY APPROVAL WHAT IS HEALTH RESEARCH AUTHORITY APPROVAL? Health Research Authority (HRA) Approval is a new process for the NHS in England that assesses a research
More informationConducting Clinical Trials of Investigational Medicinal Products
Title: Outcome Statement: Written By: Reviewed By: Conducting Clinical Trials of Investigational Medicinal Products Researchers in the Trust and research partners will be informed about the procedures
More informationRESEARCH SUPPORT SERVICES FRAMEWORK. Streamlining the management and governance of R&D studies in the NHS
RESEARCH SUPPORT SERVICES FRAMEWORK Streamlining the management and governance of R&D studies in the NHS Page 1 of 22 Contents 1. INTRODUCTION... 3 How to use this document... 3 Background... 4 Purpose
More informationPhase 1 studies and The Over- Volunteering Prevention System (TOPS)
Research Department STANDARD OPERATING PROCEDURE Phase 1 studies and The Over- Volunteering Prevention System () SOP Number C129 Version Number 1.0 Date effective 18 June 2018 Author Luke Barron Related
More informationEthical Approval. Document Number: 012
Ethical Approval Document Number: 012 Version: 1 Ratified by: RFL Committee Date ratified: 03.06.2014 Name of originator/author: Directorate: Department: Name of responsible individual: Liba Stones, Manager
More informationEnd of Study Notification, Close-Out and Reporting Sponsored Research. Noclor/Spon/S11/01. SOP Reference ID:
End of Study Notification, Close-Out and Sponsored Research SOP Reference ID: Noclor/Spon/S11/01 Version Number 1.0 Effective Date: 6 th June 2016 It is the responsibility of all users of this SOP to ensure
More informationResearch Study Amendments
REFERENCE: VERSION NUMBER: 3.2 EFFECTIVE DATE: 05-02-18 REVIEW DATE: 05-02-20 AUTHOR: Clinical Trials Manager; Clinical Trials Officer REVIEWED BY: R&I Senior Team APPROVED BY: Deputy Director of Research
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)
More informationRESEARCH IN HUMAN SUBJECTS OTHER THAN CLINICAL TRIALS OF INVESTIGATIONAL MEDICINAL PRODUCTS
Page 1 of 5 RESEARCH IN HUMAN SUBJECTS OTHER THAN CLINICAL TRIALS OF INVESTIGATIONAL MEDICINAL PRODUCTS After ethical review guidance for sponsors and investigators This document sets out important guidance
More informationHealth Research Authority (HRA) What do you need to know?
Health Research Authority (HRA) What do you need to know? Background why another change? Cohorts Cohort Type of Study Live date 1 Health services research not requiring REC review 11 th May 2015 2 Studies
More informationSponsorship of Clinical Research Studies
Sponsorship of Clinical Research Studies Category: Summary: Equality Impact Assessment undertaken: Policy The UK Policy Framework for Health and Social Care 2017 (UKPF) and The Medicines for Human Use
More informationRESEARCH AUDIT Standard Operating Procedure
Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor
More informationHRA Approval in Primary Care Settings Principles of Study Set-Up
HRA Approval in Primary Care Settings: Principles of Study Set-Up Document Title: HRA Approval in Primary Care Settings Principles of Study Set-Up Version Number: 2.0 Issue Date: 09 March 2017 Author:
More informationResearch Study Close-down and Archiving Procedures
Title: Research Study Close-down and Archiving Procedures Outcome Statement: To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
More informationTrial oversight SOP for HEY-sponsored CTIMPs
R&D Department Trial oversight SOP for HEY-sponsored CTIMPs Hull And East Yorkshire Hospitals NHS Trust 2010 All Rights Reserved No part of this document may be reproduced, stored in a retrieval system
More informationNIHR CRN Quarterly Performance Report Quarter /18
NIHR CRN Quarterly Performance Report Quarter 3 2017/18 Public Version: Version 1.0 1 March 2018 Delivering research to make patients, and the NHS, better This document sets out the metrics and commentary
More informationMHRA regulatory centre and Research Ethics Service (RES) combined ways of working pilot Instructions to sponsors (version 2.1)
MHRA regulatory centre and Research Ethics Service (RES) combined ways of working pilot Instructions to sponsors (version 2.1) Document purpose: The purpose of this document is to provide instructions
More informationCombined trial of an investigational medicinal product and an investigational medical device
Welcome to the Integrated Research Application System IRAS Project Filter The integrated dataset required for your project will be created from the answers you give to the following questions. The system
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number End of Study Notification and Premature Discontinuation of a Study SOP-RES-025 Version Number 2 Issue Date 29 th Sep 2016 Effective Date 10 th Nov 2016
More informationStandard Operating Procedure Research Governance
Research and Enterprise Standard Operating Procedure Research Governance Title: Termination or Suspension of a Research Study SOP Reference Number: QUB-ADRE-020 Date prepared 13 August 2008 Version Number:
More informationSTANDARD OPERATING PROCEDURE SOP 725 CAPACITY, CAPABILITY AND RISK ASSESSMENT OF TRIALS HOSTED BY NNUH
STANDARD OPERATING PROCEDURE SOP 725 CAPACITY, CAPABILITY AND RISK ASSESSMENT OF TRIALS HOSTED BY NNUH Version 1.0 Version date 13.12.2016 Effective date 13.12.2016 Number of pages 9 pages Review date
More informationNRES Committee East of England - Cambridge Central Royal Standard Place Nottingham NG1 6FS
22 April 2015 NRES Committee East of England - Cambridge Central Royal Standard Place Nottingham NG1 6FS Professor Willem Ouwehand Wellcome Trust Sanger Institute, Honorary NHSBT Consultant in Haematology.
More informationR&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:
Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved
More informationSTUDY CLOSURE AND ARCHIVING
STUDY CLOSURE AND ARCHIVING DOCUMENT NO.: CR009 v2.0 AUTHOR: Lynn Smith ISSUE DATE: 15 August 2016 EFFECTIVE DATE: 29 August 2016 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research
More informationStandard Operating Procedure
Standard Operating Procedure Number: UM/UoM TMF/SOP08/6.0 Title: The Creation and Maintenance of Trial Master Files and Essential Documentation Version: 6.0 () Effective Date: Author: Mrs Catherine Barrow
More informationPharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs
Joint Research Management Office (JRMO) Standard Operating Procedure (SOP) for: Pharmacovigilance and safety reporting for sponsored ATIMPs/CTIMPs SOP Number: 26a Version Number: 13.0 Effective Date: 31
More informationTrial Committees SOP Number: 47 Version Number: 2.0 Effective Date: 01/02/2017 Review Date: 01/02/2019
Standard Operating Procedures (SOP) for: Trial Committees SOP Number: 47 Version Number: 2.0 Effective Date: 01/02/2017 Review Date: 01/02/2019 Author: Reviewer: Reviewer: Authorisation: Name / Position:
More informationLCRN Guidance Suite. V1.0 March Document Ref No: D05. Version 1.0 March 2016 Page 1 of 8
LCRN Guidance Suite Provision of good practice for Sponsors to enable assesing, arranging and confirming local capacity and capability for participating organisations delivering CRN Portfolio studies V1.0
More informationDetails: Approval: Distribution & Storage:
Details: Author: Neville Young Quality Assurance Manager SOP Pages: Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person approving
More informationSTUDY DOCUMENTS. DOCUMENT NO.: CR007 v4.0. Marise Buçukoğlu ISSUE DATE: 07 MAR 2017 EFFECTIVE DATE: 21 MAR INTRODUCTION
STUDY DOCUMENTS DOCUMENT NO.: CR007 v4.0 AUTHOR: Marise Buçukoğlu ISSUE DATE: 07 MAR 2017 1 INTRODUCTION 1.1 The Academic & Clinical Central Office for Research & Development (ACCORD) is a joint office
More informationSubmission of comments on COMMISSION NOTICE ON THE APPLICATION OF ARTICLES 3, 5 AND 7 OF REGULATION (EC) NO 141/2000 ON ORPHAN MEDICINAL PRODUCTS
Ref. Ares(2016)807620-16/02/2016 15 February 2016 Submission of comments on COMMISSION NOTICE ON THE APPLICATION OF ARTICLES 3, 5 AND 7 OF REGULATION (EC) NO 141/2000 ON ORPHAN MEDICINAL PRODUCTS Response
More informationComparison of admission rates to neonatal units between PO screening and non-po screening Units
London - Westminster Research Ethics Committee 4 Minshull Street Manchester M1 3DZ Telephone: 0207 104 8012 Please note: This is the favourable opinion of the REC only and does not allow you to start your
More informationSTANDARD OPERATING PROCEDURE SOP 410. Set up and Initiation of an Investigator Site
STANDARD OPERATING PROCEDURE SOP 410 Set up and Initiation of an Investigator Site Version 1.2 Version date 4.01.2017 Effective date 5.07.2017 Number of pages 13 Review date July 2019 Author Role NNUH
More informationStandard Operating Procedure (SOP) for the Development, Management & Control of Research-Related SOPs
Standard Operating Procedure (SOP) for the Development, Management & Control of Research-Related SOPs For Completion by SOP Author Reference Number Version Document Author(s) Document Reviewer(s) PHT/RDSOP/001
More informationIndex of Standard Operating Procedures for all research Sponsored by the UHL
University Hospitals of Leicester NHS Trust () Index of Standard Operating Procedures for all research Sponsored by the March Please note that with effect from 2015, all SOPs and Appendices use the same
More informationAuthor Signature: Date: 11 October 2017 The author is signing to confirm the technical content of this document
MELBOURNE CHILDREN S TRIALS CENTRE (MCTC) Guideline document title: Developing, amending and complying with research protocols Version: 2.0 Author: Melbourne Children s Trials Centre (MCTC) Author Signature:
More informationHouse of Commons Science and Technology Committee: Inquiry on clinical trials and disclosure of data
House of Commons Science and Technology Committee: Inquiry on clinical trials and disclosure of data Evidence submitted by the Medical Research Council, 26 February 2013 Introduction 1. The Medical Research
More informationDate : Date of start of procedure: Authorisation/ positive opinion :
Substantial Amendment Notification Form (Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use,
More informationSTANDARD OPERATING PROCEDURE SOP 320. Developing a Research Protocol
STANDARD OPERATING PROCEDURE SOP 320 Developing a Research Protocol Version 2.1 Version date 26.03.2017 Effective date 26.03.2017 Number of pages 14 Review date April 2019 Author NNUH UEA Joint Research
More informationRESEARCH AND INNOVATION (R&I) Research Capacity and Capability Assessment Guidance
RESEARCH AND INNOVATION (R&I) Research Capacity and Capability Assessment Guidance Title: Prepared for: Author: Purpose of document: Research Capacity, Capability and Delivery Guidance Research & Innovation
More informationSTANDARD OPERATING PROCEDURE SOP 310
STANDARD OPERATING PROCEDURE SOP 310 DEVELOPMENT OF PARTICIPANT INFORMATION SHEET AND INFORMED CONSENT FORM Version 1.3 Version date 28.03.2017 Effective date 28.03.2017 Number of pages 8 Review date April
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More informationStep-by-Step Completion Guide
Step-by-Step Completion Guide For the NIHR CRN Industry Costing Template Secondary Care Version: May 2017 Page 1 of 30 Step-by-Step Completion Guide for the NIHR CRN Industry Costing Templates Document
More informationRD SOP32 Gaining MHRA Approval
RD SOP32 Gaining MHRA Approval Version Number: 1.0 Name of originator/author: Dr Lloyd Gregory Name of responsible committee: R&I Committee Name of executive lead: Medical Director & Director of Quality
More informationTrial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products
1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible
More informationCollaborative working between sponsors and NHS organisations in England for HRA Approval studies, where no formal
Collaborative working between sponsors and NHS organisations in England for HRA Approval studies, where no formal confirmation of capacity and capability is required. This document provides information
More informationStep-by-Step Completion Guide
Step-by-Step Completion Guide For the NIHR CRN Industry Costing Templates Primary Care Version: May 2017 Page 1 of 37 Step-by-Step Completion Guide for the NIHR CRN Industry Costing Templates Document
More informationWriting a Protocol for CTIMPs
REFERENCE: VERSION NUMBER: 4.0 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: REVIEWED BY: APPROVED BY: CONTROLLER: Clinical Trials Manager; Clinical Trials Officer Research & Innovation Group
More informationThe EFGCP Report on The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria
The Procedure for the Ethical Review of Protocols for Clinical Research Projects in Europe (Update: April 2011) Bulgaria Question 1: What laws or regulations apply to an application for conducting a clinical
More informationSupporting and applying research in the NHS. 1. Overview
Supporting and applying research in the NHS 1. Overview Improving commercial research set-up Recap of ongoing activities NHS England and the National Institute for Health Research (NIHR) have published
More informationNIHR CRN High Level Objectives Quarterly Performance Report. Quarter /16
NIHR CRN High Level Objectives Quarterly Performance Report 2015/16 Public Version: Version 1 23 February 2016 1 Preface Scope of the NIHR CRN HLOs Quarterly Performance Summary Report This document sets
More informationGuidance on conducting consultations in the HRA Internal HRA guidance only
Guidance on conducting consultations in the HRA Internal HRA guidance only Author: Amanda Hunn Date of Release: 19 th February 2015 Version No. & Status: v.1.0 Final Approved by: EMT Supersedes Version:
More informationHRA Statement of Activities
HRA Statement of Activities for Participating NHS Organisations in England (template version 4.0) For non-commercial studies, one Statement of Activities should be completed as a template for each site
More informationCode break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known.
1. INTRODUCTION This SOP has been produced in accordance with Medicines for Human Use (Clinical Trials) Regulations 2004. This SOP will outline the procedure for breaking the study code in a NUH sponsored
More informationIMP Management and Accountability
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Archiving and the Destruction of Records SOP-RES-028 Version Number 2 Issue Date 08 th Dec 2015 Effective Date 22 nd January 2016 Review Date 22 nd January
More informationStandard Operating Procedure. GCP Auditing of Research Studies. SOP effective: 23rd January 2018 Review date: 23rd January 2020
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-16-005 GCP Auditing of Research Studies SOP effective: 23rd January 2018 Review date: 23rd January 2020 SOP author signature: Signed copy
More informationInvestigator Site File Index (CTIMP)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol Current version plus all previous versions (or provide file note to detail location of previous
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Maintaining Study Files SOP-RES-014 Version Number 2 Issue Date 08 th Dec 2015 Effective Date 22 nd January 2016 Review Date 22 nd January 2018 Author(s)
More informationDate : Date of start of procedure: Authorisation/ positive opinion :
Substantial Amendment Notification Form (Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use,
More informationETHICS, IRAS & DATA PROTECTION
ETHICS, IRAS & DATA PROTECTION Clinical Research Methods Course 14 th March 2017 Priyanthi Dias Senior Trials Coordinator Adult CriDcal Care Research Unit Queen Mary University of London p.dias@qmul.ac.uk
More informationGlaxoSmithKline (GSK) Response to World Health Organization International Clinical Trials Registry Platform (ICTRP) Consultation September 2005
GlaxoSmithKline (GSK) Response to World Health Organization International Clinical Trials Registry Platform (ICTRP) Consultation September 2005 Introduction GlaxoSmithKline (GSK) is committed to enhancing
More informationDocument Title: Handling of drug alerts and recalls of IMPs
Document Title: Handling of drug alerts and recalls of IMPs Document Number: SOP074 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager,
More informationNIHR Local Clinical Research Networks
NIHR Local Clinical Research Networks Annual Plans 2014-15 Guidance WORKING DRAFT Version 0.4 WORKING DRAFT v0.4 Document Control This document is updated and issued annually by the national CRN Coordinating
More informationR&D Administration Manager. Research and Development. Research and Development
Document Title: Document Number: Trial Closure and End of Trial SOP021 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D Administration
More informationNHS R&D Forum Response CRN Study Support Service Effective Study Start-Up SOP. Version Consultation Draft, 15 JUNE 2015
NHS R&D Forum Response CRN Study Support Service Effective Study Start-Up SOP. Version Consultation Draft, 15 JUNE 2015 FINAL Version 1.0, July 22nd 2015 1. Introduction and Method The Forum working groups
More informationRDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust
RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs Greater Manchester Mental Health NHS Foundation Trust Title of Standard Operating Procedure: RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs
More informationStandard Operating Procedure. Vendor Management
REFERENCE: VERSION NUMBER: 2.0 EFFECTIVE DATE: 28-03-18 REVIEW DATE: 28-03-20 AUTHOR: Clinical Trials Manager, Contracts & Quality Management Officer REVIEWED BY: Research & Innovation Group APPROVED BY:
More informationIndex of Standard Operating Procedures for all research Sponsored by the UHL
University Hospitals of Leicester NHS Trust () Index of Standard Operating Procedures for all research Sponsored by the October Please note that with effect from 2015, all SOPs and Appendices use the same
More informationScotland A REC 2 nd Floor Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG
Scotland A REC 2 nd Floor Waverley Gate 2-4 Waterloo Place Edinburgh EH1 3EG Telephone: 0131-465-5679 19 February 2016 Professor Karim Brohi Professor of Trauma Science Queen Mary University of London
More informationPolicies, Procedures, Guidelines and Protocols
Policies, Procedures, Guidelines and Protocols Document Details Title Salary on Appointment Guidance Trust Ref No 1350-34181 Local Ref (optional) Main points the document The purpose of this guidance is
More informationLOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office
LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough
More informationStandard Operating Procedure for Archiving
Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member
More informationRDSOP28 Randomisation and Unblinding in Clinical Trials of an Investigational Medicinal Product (CTIMPs)
RDSOP28 Randomisation and Unblinding in Clinical Trials of an Investigational Medicinal Greater Manchester Mental Health NHS Foundation Trust Title of Standard Operating Procedure: Document Summary: Document
More informationResearch Governance Policy and Procedure
Research Governance Policy and Procedure Version: 5 Name of originator/author: Name of executive lead: Date ratified: Review date: APPLICABLE TO: All staff. EXECUTIVE SUMMARY Dr Lisa Austin- University
More informationCAREER BREAK POLICY HR25.CB.1.1. Document Reference. Date Ratified 14 November Release Date 5 February Review Date February 2017
CAREER BREAK POLICY Document Reference Document Status Target Audience HR25.CB.1.1 Final All Staff Date Ratified 14 November 2013 Ratified By Policy Committee Release Date 5 February 2014 Review Date February
More informationStandard Operating Procedure. GCP Auditing of Research Studies
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-16-003 GCP Auditing of Research Studies SOP effective: 09 June 2017 Review date: 09 June 2019 SOP author signature: SIGNED COPY HELD WITHIN
More informationJoint Research Office
Office Location: 1 st Floor Maple House 149 Tottenham Court Road London W1T 7DN Joint Research Office Tel: 020 3447 5557 Fax: 020 3447 9937 Website: www.uclh.nhs.uk; www.ucl.ac.uk; www.ucl.ac.uk/jro Postal
More informationStandard Operating Procedures
Standard Operating Procedures 6.0 Protocol development History Version Date Author Reason 1.1 10 th Jan 2006 Contributing New procedure authors 1.2 25 th Feb 2007 S Whicker Administrative update 1.3 11
More informationLouise Brook Clinical Trials Quality Monitor. Date
Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person
More informationCONSULTANT CONTRACT. Table of Contents
CONSULTANT CONTRACT Table of Contents Page THE POST... 2 THE WORK... 3 OTHER CONDITIONS OF EMPLOYMENT... 7 PAY... 8 PENSION... 10 LEAVE AND HOLIDAYS... 10 OTHER ENTITLEMENTS... 10 Version 1 October 2003
More informationMeeting sponsor s criteria : strategy to collaborate, engage and deliver
Meeting sponsor s criteria : strategy to collaborate, engage and deliver Frédérique Couttet Clinical Trial Manager 4th Annual Outsourcing in Clinical Trials Europe Brussels, Switzerland, May 21 22, 2014
More informationA step by step guide to using IRAS to apply to conduct research in or through the NHS/HSC.
A step by step guide to using IRAS to apply to conduct research in or through the NHS/HSC. 28 June 2017 Summary All project-based research conducted in or through the NHS/HSC in England, Northern Ireland,
More informationStandard Operating Procedure
Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if
More informationThe role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU)
in partnership with The role of the Clinical Trials Unit Emma Hall PhD CStat Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU) CTRad Clinical Trials Workshop 14/10/2014 What is
More informationAPPLICANT'S CHECKLIST
APPLICANT'S CHECKLIST Research tissue bank (or other research biobank) REC Ref: Title of Tissue Bank: Applicant's Name: Name of Designated Individual: Please complete this checklist and send it with your
More informationDocument Title: Site Recruitment and Initiation for Papworth Sponsored Studies
Document Title: Site Recruitment and Initiation for Papworth Sponsored Studies Document Number: SOP015 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For
More informationWriting a Protocol to Good Clinical Practice (GCP)
This is a controlled document. The master document is posted on the JRCO website and any print-off of this document will be classed as uncontrolled. Researchers and their teams may print off this document
More informationSPARK Recruitment Process Document
Last Updated: July 25, 2017 Overview: SPARK SPARK Recruitment Process Document What is SPARK? SPARK (Simons Foundation Powering Autism Research for Knowledge) is a landmark autism research project with
More informationMarie-Claire Good, RG and GCP Manager James Rickard, Deputy Chief Pharmacist Technical Services Cheryl Lawrence, Senior Research Pharmacist
Standard Operating Procedures (SOP) for: IMP Management BH/QMUL Sponsored CTIMPs SOP Number: 42a Version Number: 3.0 Effective Date: 14 th August 2017 Review Date: 14 th August 2019 Author: Reviewer: Reviewer:
More information